Trials / Withdrawn
WithdrawnNCT02384369
Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Synchroneuron Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs. Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.
Conditions
- Post-Traumatic Stress Disorders
- Posttraumatic Stress Disorders
- Stress Disorders, Post-Traumatic
- Post-Traumatic Stress Disorders, Combat-related
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNC-102 sustained release tablet | Sustained release oral tablet of SNC-102 |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-06-01
- Completion
- 2017-08-01
- First posted
- 2015-03-10
- Last updated
- 2016-04-18
Source: ClinicalTrials.gov record NCT02384369. Inclusion in this directory is not an endorsement.